article thumbnail

Pediatric Eczema, Eosinophilic Esophagitis Linked

The Dermatology Digest

Children and young adults with eczema or allergies or who have difficulty swallowing may have eosinophilic esophagitis, according to a review study in the Canadian Medical Association Journal (CMAJ). Most patients (75%) have at least 1 atopic (allergic) condition, such as food or environmental allergies, asthma, or eczema.

Eczema 74
article thumbnail

Oh, The Places Dermatology Will Go in 2024!

The Dermatology Digest

Dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc., Peter Lio, MD, a Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine and a partner at Medical Dermatology Associates of Chicago, agrees that it is going to be a big year for eczema patients and the doctors who treat them. “I

article thumbnail

AD Pipeline Watch: Aslan Reports “Spectacular Results” in Phase 2 Study of Eblasakimab That Included Some Dupilumab-experienced Patients

The Dermatology Digest

Adult atopic dermatitis (AD) patients previously treated with dupilumab (Dupixent, Regeneron and Sanofi) who received 400mg eblasakimab weekly achieved Eczema Area Severity Index (EASI) 90, and 66.7% achieved a Validated Investigator Global Assessment (vIGA) score of 0 or 1 after 16 weeks compared to 14.3%

article thumbnail

Off-label Pearl: Exploring the Role of Narrowband UVB Phototherapy Plus Oral JAK Inhibitors in Vitiligo

The Dermatology Digest

Watch Now Chronic Hand Eczema 101 Jonathan Silverberg, MD, PhD, MPH Chronic hand eczema (CHE) symptoms can take a dramatic toll on patients’ quality of life.

article thumbnail

Sneak Peek Inside the CSU Treatment Pipeline

The Dermatology Digest

Watch Now Chronic Hand Eczema 101 Jonathan Silverberg, MD, PhD, MPH Chronic hand eczema (CHE) symptoms can take a dramatic toll on patients’ quality of life.

article thumbnail

Follow the Leaders: Osmosis Beauty

Associated Skin Care Professionals

Osmosis uses a unique combination of active ingredients that focuses on three important factors: our pharmaceutical-grade delivery system, because most aging occurs deep within the skin; our patented products that create real changes in the skin; and our unique inside-out approach that triggers collagen/elastin and plumps the volume of the face.

article thumbnail

Label Update: FDA Green Lights Dupilumab for AD Patients With Moderate-to-Severe Hand and Foot Involvement

The Dermatology Digest

Food and Drug Administration (FDA) has updated the label for dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc. and Sanofi), adding efficacy and safety data for people aged 12 years and older with atopic dermatitis (AD) and uncontrolled moderate-to-severe hand and/or foot involvement. and Sanofi report. “We